Voluntary nationwide recall: Methocarbamol (Eugia - March)
Apr. 2024Pharmacy Updates
Eugia US LLC is recalling one lot of Methocarbamol Injection, USP 1000 mg/10 mL (100 mg/mL). Methocarbamol is used for the relief of discomfort from acute, painful musculoskeletal conditions.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Eugia US LLC at 866-850-2876, option 2. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
Voluntary nationwide recall: Tyenne (Fresenius – August 2026)
Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.Aug. 2026Pharmacy Updates
Provider OnLine Login Changes for UPMC Employees
UPMC employees will now use their email address to access Provider OnLine. Authentication will occur through their UPMC credentials and network connections. If your UPMC email address has changed since joining the organization, you should use the email address associated with your Microsoft Teams chat account when logging in to Provider OnLine.Aug. 2026Important Notices
CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care
Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.Aug. 2026Education/Webinars